Coherus BioSciences, Inc. announced that on March 2, 2023, Vladimir Vexler, Ph.D., resigned from his role as Chief Scientific Officer of the Company, effective March 10, 2023, unless the effective date is extended to March 31, 2023 at Dr. Vexler's option. His resignation was due to a desire to pursue other interests and was not as a result of any disagreement with the Company or any matter relating to the Company's operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.18 USD | +4.81% | -2.24% | -34.53% |
May. 13 | Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating | MT |
May. 09 | Transcript : Coherus BioSciences, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.53% | 250M | |
+7.52% | 113B | |
+11.38% | 106B | |
+1.51% | 22.27B | |
-12.64% | 22.22B | |
-5.15% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- CHRS Stock
- News Coherus BioSciences, Inc.
- Coherus BioSciences, Inc. Announces Resignation of Vladimir Vexler as Chief Scientific Officer, Effective March 10, 2023